The challenges of targeting chronic myeloid leukemia stem cells

Clinical Lymphoma and Myeloma

Volumn 7, Issue SUPPL. 2, 2007, Pages

  Jiang, Xiaoyan ^a   Smith, Clayton ^a   Eaves, Allen ^a   Eaves, Connie ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

bcr abl targeted therapies; Drug resistance; Imatinib

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DASATINIB; GENISTEIN; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN OCT1; UNCLASSIFIED DRUG; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BCR ABL GENE; CELL POPULATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG INHIBITION; DRUG SENSITIVITY; FUSION GENE; GENE MUTATION; GENE TARGETING; GENOMIC INSTABILITY; HUMAN; LEUKEMIA CELL; NONHUMAN; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PROTEIN EXPRESSION; REVIEW; STEM CELL; TUMOR CELL; CANCER STEM CELL; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; PATHOLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; CELL DIFFERENTIATION; FUSION PROTEINS, BCR-ABL; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; TUMOR STEM CELLS;

EID: 34247843031     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.s.005     Document Type: Article

References (131)

1. Goldman JM, Melo JV. Chronic myeloid leukemia- advances in biology and new approaches to treatment. N Engl J Med 2003; 349:1451-1464.
2. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990; 247:1079-1082.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-830.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitot of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
6. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
7. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348:994-1004.
8. Ichimaru M, Ishimaru T, Mikami M, et al. Incidence of leukemia in a fixed cohott of atomic bomb survivors and controls in Hiroshima and Nagasaki, Octobet 1950 - December 1978: Technical Repott RERF TR 13-81. Hiroshima: Radiation Effects Research Foundation 1981.
9. Fauser AA, Kanz L, Bross KJ, et al. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 1985; 75:1080-1082.
10. Nitta M, Kato Y, Strife A, et al. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 1985; 66:1053-1061.
11. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49:127-167.
12. Takahashi N, Miuta I, Saitoh K, et al. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the CP as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92:4758-4763.
13. Jonas D, Lubbert M, Kawasaki ES, et al. Clonal analysis of Bcr-Abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 1992; 79:1017-1023.
14. Dube ID, Arlin ZA, Kalousek DK, et al. Nonclonal hemopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia. Blood 1984; 64:1284-1287.
15. Hogge DE, Coulombel L, Kalousek DK, et al. Nonclonal hemopoietic progenitors in a G6PD hetetozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 1987; 24:389-394.
16. Eaves CJ, Eaves AC. Progenitot cell dynamics. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, eds. Chronic Myeloid Leukemia: Biology & Treatment. London: Martin Dunitz; 2001:73-100.
17. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-880.
18. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI571/imatinib tesistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-843.
19. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pte-exist to the onset of treatment. Blood 2002; 100:1014-1018.
20. Roche-Lestienne C, Lai JL, Darre S, et al. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 2003; 348:2265-2266.
21. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-2653.
22. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-2137.
23. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
24. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005; 102:11011-11016.
25. Weisberg E, Manley PW, Breitenstein W, et al. Charactetization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129-141.
26. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541.
27. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-2551.
28. Whang J, Frei E III, Tjio JH, et al. The disttibution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood 1963; 22:664-673.
29. Rastrick JM, Fitzgerald PH, Gunz FW. Direct evidence for presence of Ph1 chromosome in erythroid cells. Br Med J 1968; 1:96-98.
30. Tough IM, Jacobs PA, Court Brown WM, et al. Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. Lancet 1963; 1:844-846.
31. Martin PJ, Najfeld V, Hansen JA, et al. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature 1980; 287:49-50.
32. Bernheim A, Berger R, Preud'Homme JL, et al. Philadelphia chromosome positive blood B lymphocytes in chronic myelocytic leukemia. Leuk Res 1981; 5:331-339.
33. Nakajima H, Zhao R, Lund TC, et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 2002; 168:643-650.
34. Gunsilius E, Duba H-C, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000; 355:1688-1691.
35. Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitot cells with hemangioblastic characteristics. Blood 2005; 105:2733-2740.
36. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19:435-441.
37. Cozzio A, Passegue E, Ayton PM, et al. Similat MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17:3029-3035.
38. Jamieson CH, Allies LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351:657-667.
39. Castor A, Nilsson L, Astrand-Grundstrom I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11:630-637.
40. Li S, Ilaria RL, Million RP, et al. The p190, p210, and p230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189:1399-1412.
41. - leukemic cells from CML patients with CP disease and then progressively decrease as they differentiate. Blood 2003; 102:418a (Abstract #1520).
42. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006; 107:4532-4539.
43. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; [Epub ahead of print].
44. Chalandon Y, Jiang X, Hazelwood G, et al. Modulation of p210bcr-abl activity in transduced primary human hematopoietic cells controls lineage reprogramming. Blood 2002; 99:3197-3204.
45. Holyoake T, Jiang X, Eaves C, et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94:2056-2064.
46. Wang JCY, Lapidot T, Cashman JD, et al. High level engraftment of NOD/ SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in CP. Blood 1998; 91:2406-2414.
47. Holyoake TL, Jiang X, Drummond MW, et al. Elucidating critical mechanisms of deregulated stem cell turnover in the CP of chronic myeloid leukemia. Leukemia 2002; 16:549-558.
48. Udomsakdi C, Eaves CJ, Lansdorp PM, et al. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 1992; 80:2522-2530.
49. Petzer AL, Eaves CJ, Lansdorp PM, et al. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996; 88:2162-2171.
50. + aldehyde dehydrogenase-positive cells with short- and long-term repopulating activity and transient responsiveness to imatinib mesylate in vivo. Blood 2004; 104:809a (Abstract #2960).
51. Bhatia M, Wang JCY, Kapp U, et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 1997; 94:5320-5325.
52. Civin CI, Almeida-Porada G, Lee M-J, et al. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 1996; 88:4102-4109.
53. Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-b2 microglobulin-null mice. J Clin Invest 2001; 107:199-206.
54. - cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol 2001; 167:3692-3698.
55. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A 2002; 99:413-418.
56. Wang JCY, Dorrell C, Ito CY, et al. Normal and leukemic human stem cells assayed in immune-deficient mice. In: Zon LI, ed. Hematopoiesis: a Developmental Approach. New York, NY: Oxford University Press; 2001: 99-118.
57. Udomsakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A 1992; 89:6192-6196.
58. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res 1998; 22:1085-1096.
59. Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001; 97:720-728.
60. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993; 12:509-516.
61. Yong ASM, Goldman JM. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:827-828.
62. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319-325.
63. Jiang X, Lopez A, Holyoake T et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999; 96:12804-12809.
64. Jiang X, Stuible M, Chalandon Y, et al. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 2003; 102:2976-2984.
65. Eaves CJ, Cashman JD, Wolpe SD, et al. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatoty protein 1a, an inhibitor of primitive normal hematopoietic cells. P Natl Acad Sci USA 1993; 90:12015-12019.
66. Cashman JD, Eaves CJ, Sarris AH, et al. MCP-1, not MIP-1a is the endogenous chemokine that cooperates with TGF-b to inhibit the cycling of primitive normal but not leukemic (CML) progenitots in long-term human marrow cultures. Blood 1998; 92:2338-2344.
67. Cashman JD, Clark-Lewis I, Eaves AC, et al. Differentiation stage-specific regulation of primitive human hematopoietic progenitot cycling by exogenous and endogenous inhibitors in an in vivo model. Blood 1999; 94:3722-3729.
68. Cashman J, Clark-Lewis I, Eaves A, et al. Stromal-derived factot 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood 2002; 99:792-799.
69. Cashman J, Dykstra B, Clark-Lewis I, et al. Changes in the proliferative activity of human hematopoietic stem cells in NOD/SCID mice and enhancement of their ttansplantability after in vivo treatment with cell cycle inhibitors. J Exp Med 2002; 196:1141-1149.
70. Cashman JD, Eaves AC, Eaves CJ. Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-b on normal and leukemic human hematopoietic progenitor cells. Leukemia 1992; 6:886-892.
71. Sing GK, Keller JR, Ellingsworth LR, et al. Transforming growth factor b selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988; 72:1504-1511.
72. Kishi K, Ellingsworth LR, Ogawa M. The suppressive effects of type b transforming growth factor (TGFb) on primitive murine hemopoietic progenitors are abrogated by interleukin-6 and granulocyte colony-stimulating factor. Leukemia 1989; 3:687-691.
73. Rizzo DFD, Eskinazi D, Axelrad AA. Interleukin 3 opposes the action of negative regulatory protein (NRP) and of transforming growth factor-b (TGF-b) in their inhibition of DNA synthesis of the erythroid stem cell BFU-E. Exp Hematol 1990; 18:138-142.
74. Hogge DE, Cashman JD, Humphries RK, et al. Differential and synergistic effects of human granulocyte- macrophage colony-stimulating factor and human granulocyte colony- stimulating factor on hematopoiesis in human long-term marrow cultures. Blood 1991; 77:493-499.
75. Otsuka T, Thacker JD, Eaves CJ, et al. Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest 1991; 88:417-422.
76. + human cells in sheep transplanted in utero 3 years previously with CML cells. Blood 2002; 100:367a (Abstract #1422).
77. Chalandon Y, Jiang X, Loutet S, et al. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL. Leukemia 2004; 18:1006-1012.
78. Jiang X, Ng E, Yip C, et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 2002; 100:3731-3740.
79. Zhang X, Ren R. BCR-ABL efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92:3829-3840.
80. Peters DG, Klucher KM, Perlingeiro RC, et al. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL- transformed hematopoietic cell line that induces leukemia in mice. Oncogene 2001; 20:2636-2646.
81. Zandstra PW, Conneally E, Petzer AL, et al. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A 1997; 94:4698-4703.
82. Dvorak P, Dvorakova D, Doubek M, et al. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia 2003; 17:2418-2425.
83. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 2002; 1:89-95.
84. Mayerhofer M, Valent P, Sperr WR, et al. BCR/ABL induces expression of vascular endothelial growth factor and its ttanscriptional activator, hypoxia inducible factor-1a, through a pathway involving phosphoinositide 3-kinase and the mammalian target of tapamycin. Blood 2002; 100:3767-3775.
85. Deininger MW, Vieira S, Mendiola R, et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000; 60:2049-2055.
86. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in CP and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125.
87. Bueno-da-Silva AE, Brumatti G, Russo FO, et al. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 2003; 10:592-598.
88. Jorgensen HG, Allan EK, Graham SM, et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005; 19:1184-1191.
89. Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99:3792-3800.
90. + progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19:1034-1041.
91. Copland M, Hamilton A, Allan EK, et al. BMS-214662 targets quiescent chronic myeloid leukemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825). Blood 2005; 106:204a (Absttact #693).
92. Dorsey JF, Cunnick JM, Lanehart R, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002; 16:1589-1595.
93. + cells. Blood 2004; 103:3167-3174.
94. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-4707.
95. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105:2093-2098.
96. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435:1267-1270.
97. Roeder I, Horn M, Glauche I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12:1181-1184.
98. Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the tate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65:8912-8919.
99. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
100. Lepper ER, Nooter K, Verweij J, et al. Mechanisms of resistance to anti-cancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6:115-138.
101. Dai H, Marbach R Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoptotein-mediated efflux. J Pharmacol Exp Ther 2003; 304:1085-1092.
102. Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesylate with human P-glycopmtein. J Pharmacol Exp Ther 2003; 307:824-828.
103. Mahon FX, Belloc F, Lagatde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101:2368-2373.
104. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18:401-408.
105. Rumpold H, Wolf AM, Gtuenewald K, et al. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33:767-775.
106. Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concenttations. Blood 2003; 102:1142.
107. Ferrao PT, Frost MJ, Siah SP, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102:4499-4503.
108. Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 2005; 19:1590-1596.
109. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66:85-94.
110. Zhou S, Scheutz JD, Bunting KD, et al. The ABC transporter Bcrp1/ ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7:1028-1034.
111. Uchida N, Dykstra B, Lyons K, et al. ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status. Blood 2004; 103:4487-4895.
112. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002; 99:507-512.
113. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64:2333-2337.
114. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate fot the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004; 104:2940-2942.
115. Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4:747-752.
116. Nakanishi T, Shiozawa K, Hassel BA, et al. Complex interaction of BCRP/ ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006; 108:678-684.
117. + cells and is inhibited by imatinib mesylate. Blood 2006; 108:1370-1373.
118. White DL, Saunders VA, Dang P, et al. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108:697-704.
119. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104:3739-3745.
120. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005; 106:1133-1134.
121. Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 1999; 18:2676-2680.
122. Brain J, Saksena A, Laneuville P. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190Bcr-Abl transgenic mice. Leuk Res 2002; 26:1011-1016.
123. Brain JM, Goodyer N, Laneuville P. Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction. Cancer Res 2003; 63:4895-4898.
124. Fialkow PJ, Martin PJ, Najfeld V, et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58:158-163.
125. Kovitz C, Kantarjian H, Garcia-Manero G, et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108:2811-2813.
126. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006; 16:92-99.
127. Sorel N, Bonnet ML, Guilliet M, et al. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004; 323:728-730.
128. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess unique properties that predict intrinsic and acquired resistance in imatinib mesylate. Blood 2006; 108:226a (Absttact #752).
129. von Bubnoff N, Veach DR, van der KH, et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105:1652-1659.
130. Flamant S, Turhan AG. Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and imatinib mesylate selection. Leukemia 2005; 19:1265-1267.
131. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib tesistance. Blood 2006; 108:319-327.